Infliximab and etanercept have distinct actions but similar effects on cytokine profiles in rheumatoid arthritis

• Published in: Cytokine (Philadelphia, Pa.) Vol. 75; no. 2; pp. 222 - 227
• Main Authors: Takeshita, Masaru, Suzuki, Katsuya, Kikuchi, Jun, Izumi, Keisuke, Kurasawa, Takahiko, Yoshimoto, Keiko, Amano, Koichi, Takeuchi, Tsutomu
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2015
• Subjects: Adult; Aged; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Cytokines - blood; Etanercept; Etanercept - therapeutic use; Female; Humans; Infliximab; Infliximab - therapeutic use; Interferon-gamma; Interleukin-6; Male; Middle Aged; Receptors, Cytokine - blood; Rheumatoid arthritis; Interferon-gamma; CDC; HDA; ΔmTSS; LDA; MDA; HAQ-DI; RA; DAS28-ESR; Interleukin-6; MTX; CCP; RF; Infliximab; Etanercept; Rheumatoid arthritis; MMP-3; IFX; ADCC; ETN

•We compared serum cytokines in RA patients treated by infliximab and etanercept.•Serum IL-6 is decreased by etanercept and infliximab treatment to the same degree.•Serum IFNγ and TNFβ are increased by infliximab treatment.•IFNγ increase is a distinctive feature of the inefficacy of infliximab treat...